| Macular edema due to diabetes mellitus
Beovu vs Susvimo
Side-by-side clinical, coverage, and cost comparison for macular edema due to diabetes mellitus.Deep comparison between: Beovu vs Susvimo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSusvimo has a higher rate of injection site reactions vs Beovu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Susvimo but not Beovu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Beovu
Susvimo
At A Glance
Intravitreal injection
Every 8-12 weeks (maintenance)
VEGF-A inhibitor
Ocular implant (intravitreal)
Every 24-36 weeks
VEGF-A antagonist
Indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Wet age-related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
Dosing
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection monthly (every 25-31 days) for first 3 doses, followed by 6 mg every 8-12 weeks.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 6 weeks (every 39-45 days) for first 5 doses, followed by 6 mg every 8-12 weeks.
Wet age-related macular degeneration, Macular edema due to diabetes mellitus 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills every 24 weeks (approximately 6 months).
Diabetic Retinopathy 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills every 36 weeks (approximately 9 months).
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any excipient in BEOVU
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to ranibizumab products or any excipient in SUSVIMO
Adverse Reactions
Most common (>=1%) Vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, eye pain, intraocular inflammation, intraocular pressure increased, retinal hemorrhage, vitreous detachment, conjunctivitis, retinal pigment epithelial tear, corneal abrasion, hypersensitivity, punctate keratitis, retinal tear, endophthalmitis, blindness, retinal artery occlusion, retinal detachment, conjunctival hyperemia, lacrimation increased, abnormal sensation in eye, detachment of retinal pigment epithelium, vitreous hemorrhage
Serious Endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion, intraocular pressure increase, thromboembolic events, hypersensitivity
Most common (>=10%) Conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, cataract, conjunctival disorder, vitreous hemorrhage
Serious Endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion or retraction, conjunctival bleb, postoperative decrease in visual acuity
Pharmacology
VEGF-A inhibitor; brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment that binds the three major isoforms of VEGF-A (VEGF110, VEGF121, VEGF165), blocking VEGFR-1 and VEGFR-2 interaction to suppress endothelial cell proliferation, neovascularization, and vascular permeability.
Ranibizumab is a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to multiple biologically active forms of VEGF-A, blocking interaction with VEGFR1 and VEGFR2 on endothelial cells and thereby inhibiting neovascularization and vascular leakage.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Beovu
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Susvimo
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Beovu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Susvimo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Beovu
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Susvimo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SusvimoView full Susvimo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.